DE60239059D1 - Verfahren und zusammensetzungen zur hemmung, prävention oder verringerung des tumorzellwachstums beingen einer antiöstrogen-therapie resistent sind - Google Patents
Verfahren und zusammensetzungen zur hemmung, prävention oder verringerung des tumorzellwachstums beingen einer antiöstrogen-therapie resistent sindInfo
- Publication number
- DE60239059D1 DE60239059D1 DE60239059T DE60239059T DE60239059D1 DE 60239059 D1 DE60239059 D1 DE 60239059D1 DE 60239059 T DE60239059 T DE 60239059T DE 60239059 T DE60239059 T DE 60239059T DE 60239059 D1 DE60239059 D1 DE 60239059D1
- Authority
- DE
- Germany
- Prior art keywords
- therapy
- resistant
- inhibiting
- compositions
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000002560 therapeutic procedure Methods 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000004565 tumor cell growth Effects 0.000 title 1
- 229940046836 anti-estrogen Drugs 0.000 abstract 3
- 230000001833 anti-estrogenic effect Effects 0.000 abstract 3
- 239000000328 estrogen antagonist Substances 0.000 abstract 3
- 102100037632 Progranulin Human genes 0.000 abstract 2
- 101710114165 Progranulin Proteins 0.000 abstract 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 abstract 2
- 230000000144 pharmacologic effect Effects 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000012472 biological sample Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 229960001603 tamoxifen Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measurement Of Resistance Or Impedance (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/880,842 US6881548B2 (en) | 1997-05-23 | 2001-06-15 | Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy |
| PCT/US2002/018550 WO2002102306A2 (en) | 2001-06-15 | 2002-06-14 | Methods and compositions for inhibiting, preventing, or reducing tumor cell growth in patients resistant to the antineoplastic effects of antiestrogen therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60239059D1 true DE60239059D1 (de) | 2011-03-10 |
Family
ID=25377233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60239059T Expired - Lifetime DE60239059D1 (de) | 2001-06-15 | 2002-06-14 | Verfahren und zusammensetzungen zur hemmung, prävention oder verringerung des tumorzellwachstums beingen einer antiöstrogen-therapie resistent sind |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6881548B2 (de) |
| EP (2) | EP1399739B1 (de) |
| JP (5) | JP4348178B2 (de) |
| KR (3) | KR101258254B1 (de) |
| CN (2) | CN100397081C (de) |
| AT (1) | ATE496635T1 (de) |
| AU (2) | AU2002315060B2 (de) |
| CA (2) | CA2450590A1 (de) |
| DE (1) | DE60239059D1 (de) |
| ES (2) | ES2531368T3 (de) |
| HK (1) | HK1083366A1 (de) |
| WO (2) | WO2002102229A2 (de) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100111928A1 (en) * | 1997-05-23 | 2010-05-06 | A & G Pharmaceutical, Inc. | Methods and kits for diagnosis tumorgenicity |
| US6309826B1 (en) | 1997-05-23 | 2001-10-30 | Ginette Serrero | 88kDa tumorigenic growth factor and antagonists |
| US8512960B2 (en) * | 1997-05-23 | 2013-08-20 | A&G Pharmaceutical, Inc. | 88kDa tumorigenic growth factor and antagonists |
| US20030215445A1 (en) | 1997-05-23 | 2003-11-20 | Ginette Serrero | Methods and compositions for inhibiting the growth of hematopoietic malignant cells |
| US6881548B2 (en) * | 1997-05-23 | 2005-04-19 | A&G Pharmaceutical, Inc. | Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy |
| US7091047B2 (en) * | 1997-05-23 | 2006-08-15 | A&G Pharmaceutical, Inc. | Methods and kits for diagnosing tumorigenicity |
| US20030219818A1 (en) * | 2002-05-10 | 2003-11-27 | Bohen Sean P. | Methods and compositions for determining neoplastic disease responsiveness to antibody therapy |
| US7411045B2 (en) * | 2002-11-19 | 2008-08-12 | A&G Pharmaceutical, Inc. | Autocrine growth factor receptor antibodies and methods |
| JP4488903B2 (ja) * | 2003-02-26 | 2010-06-23 | エイアンドジー ファーマスーティカル インコーポレイテッド | Ｂ細胞の増殖を増加させる方法 |
| EP1849480A3 (de) * | 2003-06-23 | 2013-06-26 | A & G Pharmaceutical, Inc. | Zusammensetzungen und Verfahren zur Wiederherstellung der Empfindlichkeit von Tumorzellen gegen die Antitumorbehandlung und zur Induzierung von Apoptose |
| EP1644038A2 (de) * | 2003-06-23 | 2006-04-12 | A & G Pharmaceuticals, Inc. | Zusammenetzungen und verfahren zur wiederherstellung der emfpindlichkeit von tumorzellen auf eine antitumorale therapie und einleitung von apoptose |
| WO2005011590A2 (en) * | 2003-08-01 | 2005-02-10 | A & G Pharmaceutical, Inc. | Compositions and methods for restoring sensitivity to treatment with her2 antagonists |
| JP5336479B2 (ja) | 2007-06-13 | 2013-11-06 | スリーエム イノベイティブ プロパティズ カンパニー | 固定可能なマウント材料及びその製造方法並びに使用方法 |
| US20090269773A1 (en) * | 2008-04-29 | 2009-10-29 | Nodality, Inc. A Delaware Corporation | Methods of determining the health status of an individual |
| KR101690249B1 (ko) * | 2008-09-05 | 2016-12-27 | 에이 앤드 지 파마슈티컬즈, 인코포레이티드 | 암의 진단 방법 및 암 환자의 전반적 생존 및 무질병 생존의 측정 방법 |
| MX347850B (es) | 2012-05-03 | 2017-05-16 | Medial Res Ltd | Métodos y sistemas para evaluar un riesgo de un cáncer gastrointestinal. |
| JP6148540B2 (ja) * | 2013-06-07 | 2017-06-14 | 株式会社島津製作所 | 質量分析装置を用いたグラニュリンペプチドの定量分析方法、および分析用プログラム |
| CA2992282A1 (en) * | 2015-07-14 | 2017-01-19 | Atossa Genetics Inc. | Transpapillary methods and compositions for treating breast disorders |
| SG11202002105WA (en) | 2017-09-11 | 2020-04-29 | Atossa Therapeutics Inc | Methods for making and using endoxifen |
| CN112996924A (zh) * | 2018-07-13 | 2021-06-18 | 高保真生物技术有限公司 | 液滴单细胞表观基因组谱分析用于患者分层的用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5416192A (en) | 1990-04-03 | 1995-05-16 | Bristol-Myers Squibb Company | Epithelins: novel cysteine-rich growth modulating proteins |
| CA2023030A1 (en) * | 1990-07-13 | 1992-01-14 | Robert R. Guerrero | In vitro method and probe for detecting the presence of the ring shaped particle and malignancy in humans and animals |
| US6309826B1 (en) * | 1997-05-23 | 2001-10-30 | Ginette Serrero | 88kDa tumorigenic growth factor and antagonists |
| US6881548B2 (en) * | 1997-05-23 | 2005-04-19 | A&G Pharmaceutical, Inc. | Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy |
| ES2228932T3 (es) * | 2000-08-11 | 2005-04-16 | Wyeth | Procedimiento de tratamiento del carcinoma positivo de estrogenos. |
-
2001
- 2001-06-15 US US09/880,842 patent/US6881548B2/en not_active Expired - Lifetime
-
2002
- 2002-06-14 CA CA002450590A patent/CA2450590A1/en not_active Abandoned
- 2002-06-14 CN CNB028158040A patent/CN100397081C/zh not_active Expired - Lifetime
- 2002-06-14 CN CN200810092887.6A patent/CN101584862B/zh not_active Expired - Fee Related
- 2002-06-14 KR KR1020107008529A patent/KR101258254B1/ko not_active IP Right Cessation
- 2002-06-14 JP JP2003504895A patent/JP4348178B2/ja not_active Expired - Fee Related
- 2002-06-14 AU AU2002315060A patent/AU2002315060B2/en not_active Ceased
- 2002-06-14 WO PCT/US2002/018549 patent/WO2002102229A2/en active IP Right Grant
- 2002-06-14 EP EP02741997.7A patent/EP1399739B1/de not_active Expired - Lifetime
- 2002-06-14 JP JP2003504820A patent/JP4392238B2/ja not_active Expired - Lifetime
- 2002-06-14 ES ES02741997T patent/ES2531368T3/es not_active Expired - Lifetime
- 2002-06-14 KR KR1020097007843A patent/KR100980105B1/ko not_active IP Right Cessation
- 2002-06-14 AT AT02739838T patent/ATE496635T1/de not_active IP Right Cessation
- 2002-06-14 EP EP02739838A patent/EP1404365B1/de not_active Expired - Lifetime
- 2002-06-14 WO PCT/US2002/018550 patent/WO2002102306A2/en active Application Filing
- 2002-06-14 KR KR1020037016437A patent/KR100972053B1/ko not_active IP Right Cessation
- 2002-06-14 CA CA002450666A patent/CA2450666A1/en not_active Abandoned
- 2002-06-14 ES ES02739838T patent/ES2359494T3/es not_active Expired - Lifetime
- 2002-06-14 DE DE60239059T patent/DE60239059D1/de not_active Expired - Lifetime
- 2002-06-14 AU AU2002312462A patent/AU2002312462B2/en not_active Ceased
-
2006
- 2006-04-12 HK HK06104428A patent/HK1083366A1/xx not_active IP Right Cessation
-
2009
- 2009-05-08 JP JP2009113155A patent/JP2009215302A/ja active Pending
-
2013
- 2013-04-04 JP JP2013078654A patent/JP2013139473A/ja active Pending
-
2015
- 2015-08-07 JP JP2015156532A patent/JP2015227369A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60239059D1 (de) | Verfahren und zusammensetzungen zur hemmung, prävention oder verringerung des tumorzellwachstums beingen einer antiöstrogen-therapie resistent sind | |
| ATE515575T1 (de) | Verfahren und sonden für den nachweis von krebs | |
| ATE440536T1 (de) | Verfahren zur diagnose, behandlung und prävention von knochenverlust | |
| BR0115715A (pt) | Análise de expressão de ácidos nucleìcos e polipeptìdeos úteis na diagnose e tratamento de câncer da próstata | |
| BR0212211A (pt) | Diagnóstico de carcinomas | |
| HUP0200186A2 (en) | Use of casb616 polypeptides and polynucleotides for cancer treatment | |
| ATE470723T1 (de) | Genexpressionsmarker für die prognose von brustkrebs | |
| NO20052928L (no) | Nye kjemiske forbindelser | |
| ATE337413T1 (de) | Methoden zur verbesserung der sensitivität und spezifität von screeningverfahren für krebs und krebs-vorstufen | |
| ATE538809T1 (de) | Verfahren zur auswahl von geeigneten patienten für den wt1-impfstoff | |
| ATE458201T1 (de) | Methode zur beurteilung von rheumatoider arthritis durch bestimmung von anti-ccp und interleukin 6 | |
| HK1149956A1 (en) | Method of assessing colorectal cancer from a stool sample by use of the marker combination calprotectin and hemoglobin/haptoglobin complex | |
| DE60326748D1 (de) | Verfahren zur identifizierung des brustkrebsrisikos | |
| BRPI0515794A (pt) | processos para avaliar pacientes com leucemia mielóide aguda | |
| ATE350662T1 (de) | Markerproteine für prostatakrebs | |
| BRPI0607016A2 (pt) | marcadores polipeptìdicos para o diagnóstico de cáncer de próstata | |
| ATE238551T1 (de) | Homogene nachweisverfahren zur bestimmung der phosphorylierungsaktivitäten von biologischem material | |
| DE602005013430D1 (de) | Verwendung von asc als marker für kolorektalkarzinome | |
| DE602005023329D1 (de) | VERFAHREN ZUR DIAGNOSE NICHT-KLEINZELLIGER LUNGENKARZINOME ÜBER DIE tRNA-DIHYDROURIDIN-SYNTHASEAKTIVITÄT VON URLC8 | |
| DE60025170D1 (de) | Diagnostisches verfahren für asthma | |
| WO2003068268A3 (en) | Treatment, diagnosis and imaging of disease | |
| BR0115689A (pt) | Análise de expressão de inibidor de diferenciação de ácidos nucléicos e polipeptìdeos úteis na diagnose e tratamento de câncer da próstata | |
| HUP0303905A2 (hu) | KIAA-nukleinsavak és -polipeptidek prosztatarák diagnosztizálására és gyógykezelésére alkalmas expressziós analízise | |
| EP1724579A3 (de) | Verfahren zur Diagnose von Prostatakrebs und zur Analyse von Prostatatumoren | |
| WO2007127002A3 (en) | Protein markers of responsiveness to type iii receptor tyrosine kinase inhibitors |